0001144204-16-099211.txt : 20160505 0001144204-16-099211.hdr.sgml : 20160505 20160505154409 ACCESSION NUMBER: 0001144204-16-099211 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160505 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160505 DATE AS OF CHANGE: 20160505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870652870 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36333 FILM NUMBER: 161623431 BUSINESS ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 BUSINESS PHONE: (832) 742-1357 MAIL ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 8-K 1 v439081_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 5, 2016

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36333

87-0652870

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas	77401
(Address of principal executive offices)	(Zip Code)

(832) 742-1357

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On May 5, 2016, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings to Present at 18^th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference.” A copy of such press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number

Description

99.1

Press Release dated May 5, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIO-PATH HOLDINGS, Inc.

Dated: May 5, 2016	By: /s/ Peter H. Nielsen
	Peter H. Nielsen
	President and Chief Executive Officer

EXHIBIT INDEX

Exhibit
Number

Description

99.1

Press Release dated May 5, 2016

EX-99.1 2 v439081_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

HOUSTON—May 5, 2016 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Ana Tari Ashizawa, Ph.D., Director of Research, will deliver an oral presentation titled, “Clinical Studies of BP1001, a drug candidate utilizing DNAbilize™ Antisense DNA Technology, in Hematologic Malignancies,” at the 18^th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference. Dr. Ashizawa’s presentation will take place on Thursday, May 12^th at 2pm Pacific Time at the Long Beach Convention and Entertainment Center in Long Beach, CA.

“We are delighted to have Dr. Ashizawa highlight the potential of our DNAbilize™ antisense technology for the treatment of hematologic cancers amid an audience of leading researchers and drug developers in the field, elevating the awareness of our novel antisense DNA technology as we advance this promising lead program into Phase II studies,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Clinical studies of BP1001, the lead DNAbilize™ drug candidate that targets Grb2 protein, demonstrated anti-leukemic activity and blast reduction. AraC is the frontline therapy for acute myeloid leukemia (AML) patients. Preclinical studies indicated that BP1001 enhanced AraC cytotoxicity in AML cells. Clinical studies have demonstrated the safety of the BP1001 + AraC combination in the safety segment of the Phase II trial. Results to date demonstrate this novel drug combination is well tolerated with positive anti-leukemic effects including several complete remissions in patients with treatment-resistant AML.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize^™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at http://www.biopathholdings.com.

# # #

Contact Information:

Investors

Will O’Connor

Stern Investor Relations, Inc.

212-362-1200

will@sternir.com

Doug Morris

Investor Relations

Bio-Path Holdings, Inc.

832-742-1369

Media

Tony Plohoros

6 Degrees

908-591-2839

tplohoros@6degreespr.com

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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